PSN 9301

Drug Profile

PSN 9301

Alternative Names: P 9301; P93/01; PSN9301

Latest Information Update: 04 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Probiodrug
  • Developer Prosidion
  • Class Antihyperglycaemics; Small molecules
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 30 Nov 2007 Discontinued - Phase-II for Type-2 diabetes mellitus in Germany (PO)
  • 10 Sep 2007 Clinical data added to the drug interactions section
  • 18 Jan 2006 (OSI) Prosidion is the diabetes and obesity business unit of OSI Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top